[CXCL5 inhibits tumor immune of lung cancer via modulating PD1/PD-L1 signaling].

Xie, X H; Wang, Y J; Lei, W; Gao, H J; Duan, Y J; Hou, X

Xie, X H; Wang, Y J; Lei, W; Gao, H J; Duan, Y J; Hou, X.

Afiliação

Xie XH; Department of Oncology, the First Affiliated Hospital of Henan University, Kaifeng 475000, China.
Wang YJ; Department of Gynaecology and Obstetrics, the First Affiliated Hospital of Henan University, Kaifeng 475000, China.
Lei W; Department of Ultrasonography, the First Affiliated Hospital of Henan University, Kaifeng 475000, China.
Gao HJ; Department of Oncology, the First Affiliated Hospital of Henan University, Kaifeng 475000, China.
Duan YJ; Department of Oncology, the First Affiliated Hospital of Henan University, Kaifeng 475000, China.
Hou X; Department of Oncology, the First Affiliated Hospital of Henan University, Kaifeng 475000, China.

Zhonghua Zhong Liu Za Zhi ; 44(5): 382-388, 2022 May 23.

Article em Zh | MEDLINE | ID: mdl-35615793

Assuntos

Antígeno B7-H1; Quimiocina CXCL5; Neoplasias Pulmonares; Animais; Antígeno B7-H1/metabolismo; Linfócitos T CD8-Positivos; Quimiocina CXCL5/metabolismo; Humanos; Neoplasias Pulmonares/imunologia; Neoplasias Pulmonares/metabolismo; Neoplasias Pulmonares/patologia; Camundongos; Camundongos Endogâmicos C57BL; Receptor de Morte Celular Programada 1/metabolismo

Palavras-chave

CXC chemokine ligand 5; Lung neoplasms; Programmed death-1; Programmed death-ligand 1; Tumor immune

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quimiocina CXCL5 / Antígeno B7-H1 / Neoplasias Pulmonares Limite: Animals / Humans Idioma: Zh Revista: Zhonghua Zhong Liu Za Zhi Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google